Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAM Induction Therapy in Newly-diagnosed Adult Patients With AML
NCT07490288Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2026
- Primary completion
- Oct 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Open-label, single-arm trial of venetoclax, azacitidine and mitoxantrone hydrochloride liposome in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete Remission Rate at 84 days. Started May 2026; status: recruiting.
02
Drugs
venetoclaxazacitidinemitoxantrone hydrochloride liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07490288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490288.